-+ 0.00%
-+ 0.00%
-+ 0.00%

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Barchart·12/22/2025 09:15:00
Listen to the news

- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -

- The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines -

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.